Rusfertide is a synthetic peptide containing aliphatic, aromatic, and charged residues that produce varied secondary-structure motifs. Researchers examine it to evaluate peptide-receptor interactions, conformational flexibility, and solvent-driven behavior. Its functional arrangement supports mechanistic and structural exploration.
CAT No: R2421
CAS No:1628323-80-7
Synonyms/Alias:Rusfertide;Rusfertide [USAN];XM71MYX0IQ;PTG-300FB;PTG-300;UNII-XM71MYX0IQ;RUSFERTIDE [INN];1628323-80-7;WHO 11456;Isovaleryl-Asp-Thr-His-Phe-Pro-cyclo(Cys-Ile-Lys(palm-gamma-Glu)- Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys)-Lys-NH2;L-LYSINAMIDE, N-(3-METHYL-1-OXOBUTYL)-L-.ALPHA.-ASPARTYL-L-THREONYL-L-HISTIDYL-L-PHENYLALANYL-L-PROLYL-L-CYSTEINYL-L-ISOLEUCYL-N6-(N-(1-OXOHEXADECYL)-L-.GAMMA.-GLUTAMYL)-L-LYSYL-L-PHENYLALANYL-L-.ALPHA.-GLUTAMYL-L-PROLYL-L-ARGINYL-L-SERYL-L-LYSYLGLYCYL-L-CYSTEINYL-;N-(3-METHYL-1-OXOBUTYL)-L-.ALPHA.-ASPARTYL-L-THREONYL-L-HISTIDYL-L-PHENYLALANYL-L-PROLYL-L-CYSTEINYL-L-ISOLEUCYL-N6-(N-(1-OXOHEXADECYL)-L-.GAMMA.-GLUTAMYL)-L-LYSYL-L-PHENYLALANYL-L-.ALPHA.-GLUTAMYL-L-PROLYL-L-ARGINYL-L-SERYL-L-LYSYLGLYCYL-L-CYSTEINYL-L-LYSINAMIDE;Hepcidin Agonist PTG-300;Hepcidin Mimetic PTG-300;PTG300;PTG 300;ISOVALERYL-ASP-THR-HIS-PHE-PRO-CYCLO(CYS-ILE-LYS(PALM-GAMMA-GLU)-PHE-GLU-PRO-ARG-SER-LYS-GLY-CYS)-LYS-NH2;L-LYSINAMIDE, N-(3-METHYL-1-OXOBUTYL)-L-ALPHA-ASPARTYL-L-THREONYL-L-HISTIDYL-L-PHENYLALANYL-L-PROLYL-L-CYSTEINYL-L-ISOLEUCYL-N6-(N-(1-OXOHEXADECYL)-L-GAMMA-GLUTAMYL)-L-LYSYL-L-PHENYLALANYL-L-ALPHA-GLUTAMYL-L-PROLYL-L-ARGINYL-L-SERYL-L-LYSYLGLYCYL-L-CYSTEINYL-;L-Lysinamide, N-(3-methyl-1-oxobutyl)-L-alpha-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-L-cysteinyl-L-isoleucyl-N6-[N-(1-oxohexadecyl)-L-gamma-glutamyl]-L-lysyl-L-phenylalanyl-L-alpha-glutamyl-L-prolyl-L-arginyl-L-seryl-L-lysylglycyl-L-cysteinyl-, cyclic (6-->16)-disulfide;N-(3-METHYL-1-OXOBUTYL)-L-ALPHA-ASPARTYL-L-THREONYL-L-HISTIDYL-L-PHENYLALANYL-L-PROLYL-L-CYSTEINYL-L-ISOLEUCYL-N6-(N-(1-OXOHEXADECYL)-L-GAMMA-GLUTAMYL)-L-LYSYL-L-PHENYLALANYL-L-ALPHA-GLUTAMYL-L-PROLYL-L-ARGINYL-L-SERYL-L-LYSYLGLYCYL-L-CYSTEINYL-L-LYSINAMIDE;
Rusfertide, also known as PTG-300, is a synthetic hepcidin mimetic peptide that has garnered significant attention in biomedical research due to its unique ability to regulate systemic iron homeostasis. Engineered to closely resemble the endogenous hormone hepcidin, Rusfertide interacts with ferroportin, the principal cellular iron exporter, thereby modulating iron absorption and distribution throughout the body. Its peptide-based structure confers high specificity and stability, making it an invaluable tool for studies focused on iron metabolism and related disorders. Researchers are increasingly leveraging Rusfertide's targeted mechanism of action to elucidate the molecular pathways underlying iron regulation, investigate the pathophysiology of iron overload conditions, and explore novel therapeutic strategies in preclinical settings.
Iron Metabolism Research: Rusfertide is widely utilized in laboratory investigations aimed at understanding the intricate mechanisms of iron homeostasis. By mimicking the activity of endogenous hepcidin, it allows scientists to modulate ferroportin activity in cellular and animal models, providing a controlled environment to study iron absorption, recycling, and storage. This enables a deeper exploration of the regulatory networks governing iron balance, particularly in the context of genetic or acquired disruptions in hepcidin signaling. Through these studies, researchers can dissect the consequences of altered iron flux and identify potential molecular targets for future intervention.
Hematological Disorder Modeling: In the realm of hematology, PTG-300 serves as a powerful agent for modeling iron overload diseases such as hereditary hemochromatosis and beta-thalassemia. Its ability to induce hypoferremia by promoting ferroportin internalization and degradation makes it suitable for creating in vivo and in vitro models of iron-restricted erythropoiesis. These models are instrumental in evaluating the impact of iron modulation on erythroid precursor development, red blood cell maturation, and the downstream effects on hematopoietic homeostasis. As a result, scientists can better understand the interplay between iron availability and erythropoiesis, as well as test the efficacy of novel iron-regulating compounds.
Preclinical Drug Evaluation: The synthetic hepcidin mimetic is increasingly employed in preclinical studies to assess the safety and pharmacodynamic properties of iron modulators. By incorporating Rusfertide into animal models, researchers can monitor changes in serum iron levels, tissue iron distribution, and biomarkers of iron metabolism, thereby generating robust data on the compound's biological effects. These studies are critical for optimizing dosing regimens and predicting potential off-target effects, ultimately accelerating the development of innovative agents targeting iron dysregulation.
Translational Physiology Studies: PTG-300 is also a valuable asset in translational research, where it is used to bridge the gap between basic science discoveries and clinical applications. By manipulating systemic iron levels in experimental models, investigators can simulate various pathophysiological states, such as iron deficiency or overload, to examine their effects on organ function, inflammation, and metabolic processes. This approach enhances our understanding of the systemic consequences of iron imbalance and informs the design of future interventions aimed at restoring iron homeostasis in diverse disease contexts.
Biomarker Discovery and Validation: The use of Rusfertide in controlled laboratory settings facilitates the identification and validation of novel biomarkers associated with iron metabolism. By modulating iron levels in experimental systems, researchers can monitor dynamic changes in gene expression, protein profiles, and metabolite concentrations, uncovering candidate biomarkers that reflect iron status or the activity of regulatory pathways. These efforts are essential for developing sensitive diagnostic tools and for monitoring disease progression or response to iron-modulating therapies in research environments.
By supporting a wide spectrum of research directions—from fundamental iron biology to translational and preclinical investigations—Rusfertide continues to drive innovation in the study of iron metabolism. Its precise mechanism of action, coupled with its versatility in experimental design, makes it a preferred reagent for laboratories seeking to unravel the complexities of iron regulation, model hematological disorders, evaluate new therapeutic candidates, and advance biomarker discovery. As research into iron-related diseases expands, the role of PTG-300 is poised to remain at the forefront of scientific exploration, offering new insights and fostering the development of next-generation strategies for managing iron homeostasis.
1. Myotropic activity of allatostatins in tenebrionid beetles
4. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More